Wednesday, March 18, 2026 8:08:08 AM
The paper says nothing at all about DC vaccines, or any vaccines. That is just AI generated content based on the "garbage in" AC fed it.
The paper discusses how a better genetic understanding of the GBM lineage allows for proper combination drugs to be selected. Then goes on to describe experiments with a combination of OTX008 (a LGALS1 inhibitor) and Abeaciclib (a CDK4/6 inhibitor) that the analysis predicted should be effective.
This is the exact opposite of -L is.
But whatever. Since this board is willing to believe LSE nonsense and fake SEC quotes that are easy to see are garrbage, I am sure they will believe any AI generated garbage AC feeds them.
But for those who need to supplement with AI, try asking gemini the following question in a clean chat (always start by cllcking the "new chat" button so your old content is not treated as input).
It is amazing none of that DCVax-L reply
The paper discusses how a better genetic understanding of the GBM lineage allows for proper combination drugs to be selected. Then goes on to describe experiments with a combination of OTX008 (a LGALS1 inhibitor) and Abeaciclib (a CDK4/6 inhibitor) that the analysis predicted should be effective.
This is the exact opposite of -L is.
But whatever. Since this board is willing to believe LSE nonsense and fake SEC quotes that are easy to see are garrbage, I am sure they will believe any AI generated garbage AC feeds them.
But for those who need to supplement with AI, try asking gemini the following question in a clean chat (always start by cllcking the "new chat" button so your old content is not treated as input).
Based on https://www.biorxiv.org/content/10.64898/2026.02.21.707071v1.full.pdf, what would be a good treatment for GBM?
It is amazing none of that DCVax-L reply
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
